Market research
DPA.F Daito Pharmaceutical Co.,Ltd
F EUR Not available
Latest close
As of 04 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 358M
- P/E ratio
- 10.64
- Analyst target
- Not available
- Dividend yield
- 1.5%
- Beta
- 0.48
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- Not available
- Market cap
- 358M
- P/E ratio
- 10.64
- Analyst target
- Not available
- Dividend yield
- 1.5%
- Beta
- 0.48
About
About Daito Pharmaceutical Co.,Ltd
Daito Pharmaceutical Co.,Ltd. manufactures and sells pharmaceutical products worldwide. The company offers various active pharmaceutical ingredients and intermediates, prescription drugs, OTC drugs, and home-delivery medicines; formulations in various forms, such as tablets, capsules, troches, granules, and powders; and contract manufacturing services for formulations of medicinal products to pharmaceutical companies. It also sells health food products. The company was formerly known as Daito Corporation and changed its name to Daito Pharmaceutical Co.,Ltd. in 1992. Daito Pharmaceutical Co.,Ltd. was incorporated in 1942 and is headquartered in Toyama, Japan.
Research context
Daito Pharmaceutical Co.,Ltd appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the DPA.F discussion.
5 years, 7 months ago
Daito Pharmaceutical Co.,Ltd is currently in a long term uptrend where the price is trading 10.7% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.0.
Daito Pharmaceutical Co.,Ltd's total revenue rose by 6.4% to $12B since the same quarter in the previous year.
Its net income has increased by 1.8% to $1B since the same quarter in the previous year.
Based on the above factors, Daito Pharmaceutical Co.,Ltd gets an overall score of 4/5.